Showing 1771-1780 of 2152 results for "".
- I-MED Pharma Partners With Quidel to Introduce I-Lid ’N Lash, I-Relief, and SMTube to the US Markethttps://modernod.com/news/i-med-pharma-partners-with-quidel-to-introduce-i-lid-n-lash-i-relief-and-smtube-to-the-us-market/2479777/I-MED Pharma, a company specializing in dry eye diagnosis and management, announced the signing of an exclusive distribution agreement with Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems, for I-MED Pha
- Market Scope: Ophthalmic Laser Market Expected to Total $400 Million in 2018https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-400-million-in-2018/2479885/Global revenues for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total more than $400 million in 2018 and grow
- CooperVision to Launch of MyDay MiSight 1 Day Contact Lenses in Europehttps://modernod.com/news/coopervision-to-launch-of-myday-misight-1-day-contact-lenses-in-europe/2485287/CooperVision announced the upcoming launch of MyDay MiSight 1 day contact lenses in the UK and select European and surrounding markets. The new daily disposable soft contact lens combines MiSight 1 day ActivControl Technology,
- Prevent Blindness Launches Online Patient Resource on Insurance Benefits for Eye Carehttps://modernod.com/news/prevent-blindness-launches-online-patient-resource-on-insurance-benefits-for-eye-care/2484307/With open enrollment in Medicare and the Affordable Care Act Marketplace underway, Prevent Blindness has launched a new online educational resource to help individuals and families better understand their vision and eye care benefits. According to Prevent Blindness, the new guide, “Understa
- Smartlens Secures $5.2 Million to Advance FDA Clearance and Commercial Launch of miLenshttps://modernod.com/news/smartlens-secures-52-million-to-advance-fda-clearance-and-commercial-launch-of-milens/2484291/Smartlens announced the closing of an oversubscribed $5.2 million bridge financing round to accelerate the company’s FDA clearance process and support preparations for an expedited U.S. market launch of its flagship product, miLens, f
- European Commission Approves Mynzepli as a Biosimilar to Eyleahttps://modernod.com/news/european-commission-approves-mynzepli-as-a-biosimilar-to-eylea/2484127/The European Commission has granted marketing authorization for Mynzepli (aflibercept), a biosimilar to Eylea, developed by Alvotech in partnership with Advanz Pharma. The centralized authorization applies t
- Johnson & Johnson Appoints Kelly Heaps, Vice President of US Sales, Vision Carehttps://modernod.com/news/johnson-johnson-appoints-kelly-heaps-vice-president-of-us-sales-vision-care/2482879/Johnson & Johnson announced the appointment of Kelly Heaps as Vice President of US Sales, Vision Care. As the leader of the US Sales Organization, Ms. Heaps will work to accelerate sales and foster market share growth while collaborating with customers to strengthen patient outcomes.
- Sydnexis Announces European Commission Approval of Ryjunea, the First Treatment for Slowing the Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-european-commission-approval-of-ryjunea-first-treatment-for-slowing-the-progression-of-pediatric-myopia/2482839/The European Commission (EC) has granted marketing authorization for Sydnexis' SYD-101 (branded as Ryjunea), the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia.
- EssilorLuxottica to Acquire European Ophthalmology Network Optegra Clinicshttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmology-network-optegra-clinics/2482825/EssilorLuxottica and MidEuropa have entered into an agreement in which EssilorLuxottica will acquire Optegra, an integrated ophthalmology platform operating in five European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. Financial terms of the deal were
- Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEOhttps://modernod.com/news/allotex-accelerates-into-commercial-phase-and-appoints-michael-mrochen-as-new-ceo/2482755/Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and A